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Abstract  
AIM: The aim of the study was to investigate the prevalence of diabetes mellitus in privies 
diagnosed chronic obstructive pulmonary disease (COPD) patients with severe and very severe 
disease, which ware stable.  
METHODS: We investigated 100 subjects, all of them smokers, with smoking status >10 years. 
They were stratified in two groups. It was clinical, randomized, cross sectional study. Besides 
demographic parameters, functional parameters, BMI, cholesterol, LDL and HDL, and the level of 
blood sugar was measured.  
RESULTS: The prevalence of diabetes mellitus in our survey in total number of COPD patients with 
severe and very severe stage was 21%. In the very severe group were recorded significantly higher 
average values of glycaemia compared with severe group (7.67 ± 3.7 vs. 5.62 ± 0.9, p = 0.018). In 
the group with severe COPD, it was not confirmed any factor with significant predictive effect on the 
values of glycaemia. As independent significant factors that affect blood glucose in a group of very 
severe COPD were confirmed cholesterol (p <0.0001) and HDL (p = 0.018).  
CONCLUSION: These results suggest that the presence of the COPD in patients itself is a factor 
that results in the clinical presentation of diabetes mellitus Type 2. 
 
 
 
 
 
 
 
Introduction 
 
Chronic obstructive pulmonary disease 
(COPD) is defined as abnormal inflammatory 
response of the lung to noxious gases and particles. 
The main epidemiological factor is smoking [1]. COPD 
is affecting nearly 300 million people worldwide and 
killing 3 million individuals each year [2]. Clinically, 
COPD is characterized by shortness of breath, and 
chronic, mostly productive cough that persists for 
weeks to months. All patients demonstrate airflow 
limitation on lung function tests with reduced 
expiratory flow rates. The main COPD feature is lung 
inflammation, which intensifies with disease 
progression [3]. 
Comorbidities in COPD are frequent; they 
influence the prognosis of patient’s diseases. The 
most common are cardiovascular diseases, 
skeletomuscular disorders, pulmonary malignant 
tumors, metabolic syndrome and many others, and 
have significantly impact on patients' quality of life, 
exacerbation frequency, and survival, and they largely 
affect the prognosis of the disease [4, 5]. One of the 
COPD comorbidities is diabetes mellitus, as one of 
metabolic syndrome. Metabolic syndrome is defined 
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as a complex of interrelated cardiovascular risk 
factors. It has clinically relevant negative effects on 
subjects exercise capacity, as well as on health status 
and mortality [7, 8]. 
Some authors considered COPD as a novel 
risk factor for new onset type 2 diabetes mellitus via 
multiple pathophysiological alterations first of all 
nonspecific low grade inflammation that occur in the 
lung and then split over in the whole body, and is 
responsible for systemic characteristics of the disease 
[8]. Systemic inflammation, with elevated markers 
such as C-reactive protein (CRP), tumor necrosis 
factor-α (TNF-α) and interleukin-6 (IL-6), plays an 
important role in both, the progression of COPD and 
the development of insulin resistance. Smoking is one 
cause of inflammation. Smokers have a two-fold 
higher risk of developing diabetes mellitus type 2 than 
nonsmokers [9]. 
The other reasons are: oxidative stress which 
is also considered as a reason for developing lung 
inflammation, insulin resistance [26] weight gain and 
alterations in metabolism of adipocytes. Type 2 DM is 
particularly common medical disorder and a leading 
cause of morbidity and mortality worldwide [10]. 
Disturbances in glucose metabolism are more 
frequent in COPD patients than in non COPD 
individuals. Similarly, almost half of all COPD patients 
suffer from other medical problems frequently linked 
to diabetes, such as elevated blood pressure and 
higher levels of cholesterol [11].  
They are reasons for various cardiovascular 
complications in COPD patients. In many studies have 
found that DM causes an accelerated decline in lung 
functions as compared to non-diabetics. Diabetes 
especially uncontrolled is linked to worsening the 
outcomes such as (longer hospital stay and risk of 
death) in people that suffer from an exacerbation of 
COPD. The need to use of corticosteroid therapy 
during exacerbations can complicate the status of 
diabetes mellitus in those patients [12, 13]. 
The aim of the study was to investigate the 
prevalence of diabetes mellitus (Type 2) privies 
diagnosed COPD patients with severe and very 
severe stage of the disease, which was stable. 
 
 
Material and Methods 
 
We investigated 100 subjects, all of them 
smokers, with smoking status >10 years. The duration 
of COPD in these patients was more than 9 years and 
diabetes mellitus more than 5 years. Subjects with 
COPD were stratified in two groups according to 
Global Initiative for Chronic Obstructive Lung Disease 
(GOLD). 64 of them were with severe stage of the 
disease: 50% > FEV1 ≥ 30%, FEV1/FVC < 0, 70, and 
36 subjects with very severe stage of the disease: 
FEV1 < 30%, FEV1/FVC < 0, 70. It was clinical, 
randomized, cross sectional study. Besides 
demographic parameters (age, gender) and functional 
parameters, CRP (C-reactive protein) body mass 
index (BMI), cholesterol, LDL (low density lipoprotein) 
and HDL (high density lipoprotein), the level of blood 
sugar and HbA1c (Glycated hemoglobin (hemoglobin 
A1c) ware measured. 
 
Statistical analysis 
Statistical analysis of the data base was made 
in the program SPSS for Windows 17, 0. Testing of 
the distribution of the data was done with Kolmogorov 
- Smirnov and Shapiro-Wilk's test). Categorical 
variables were presented with absolute and relative 
numbers; numeric variables were shown MPC 
descriptive statistics (mean, median, rank values). 
To test the significance of differences 
between the two COPD groups, were used parametric 
and nonparametric methods for independent samples 
(Chi-square test, Student-s test, Mann-Whitney U 
test).Categorical variables were presented with 
absolute and relative numbers; numeric variables 
were shown MPC descriptive statistics (mean, 
median, rank values).To test the significance of 
differences between the two COPD groups, were 
used parametric and nonparametric methods for 
independent samples (Chi-square test, Student-s test, 
Mann-Whitney U test).To determine the correlation 
between blood sugar and certain parameters was 
used Pearson-s coefficient of linear correlation). 
Multiple regression analysis was used to determine 
significant independent factors associated with blood 
sugar levels. For statistically significant values were 
taken at p < 0.05. 
 
 
Results 
 
The prevalence of diabetes mellitus in our 
survey in total number of COPD patients with severe 
and very severe stage was 21%.  
 
Severe vs. very severe COPD 
In the men significantly more likely than 
women were registered very severe COPD (45.45% 
vs. 17.65%, p = 0.006) (Table 1). 
Table 1: The prevalence of gender in both groups of COPD 
patients 
Gender COPD (severe ) 
N = 64 
COPD (very severe) 
N = 36 
p-value 
Female  n = 34        28 (82.35%)        6 (17.65%)   p = 0.006 
Male     n = 66        36 (54.55%)      30 (45.45%) 
p (Chi-square test)  p < 0.01. 
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Patients with severe and very severe COPD 
were insignificant different age and BMI (p = 0.75 and 
p = 0.14 consequently) (Table 2).  
Table 2: The age, body mass index and functional parameters 
in both groups of patients 
Variable Group Mean ± SD Min - Max p-value 
Age (years) Severe 62.53 ± 11.3 37 - 88  
*p = 0.75 Very severe 61.83 ± 9.1 45 - 80 
BMI (kg/m2) Severe 24.22 ± 5.2 16 - 36  
*p = 0.14 Very severe 25.9 ± 5.9 19.3 - 35 
FVC L 
 
Severe 1.78 ± 0.5 0.9 - 3.28 *p < 0.01 
 Very severe 1.23 ± 0.4 0.56-1.89 
FVC% 
 
FEV1 L 
 
FEV1%                        
Severe 56.25 ± 11.2 40 - 88 *p < 0.01 
 
*p<0.01 
 
*p<0.01 
Very severe 
Severe 
Very severe 
Severe 
Very severe 
37.67 ± 12.9 
1.02 ± 0.2 
0.67 ± 0.2 
40.6 ± 6.8 
23.3 ± 5.4 
20 - 67 
0.64-1.58 
0.25-0.53 
31-50 
11-29 
FEV1/FVC% Severe 60.84 ± 6.8 48 -70 *p < 0.01 
 Very severe 52.61 ± 8.6 36 - 66 
*p ( Student-s t-test). 
 
C-reactive protein (CRP) 
In the group with very severe COPD were 
registered significantly higher values of C-reactive 
protein versus patients with severe COPD (p < 
0.0001) (Table 3). 
Table 3: The level of C-reactive protein in patients with severe 
vs very severe COPD 
Variable Group Mean ± SD Median (IQR) p-value 
 
CRP mg/L 
Severe 5.62 ± 1.6 5 (4.5 - 6.5)  
*p < 0.0001 Very severe 9.28 ± 3.2 9 (7 - 10 
P (Mann- Whitney U test). 
 
Glycemia  
In the group of patients with very severe COPD were 
recorded significantly higher average values of 
glycemia and HbA1c, compared with the group with 
severe COPD (7.67 ± 3.7 vs. 5.62 ± 0.9, p = 0.018). 
(Table 4, Table5). 
Table 4: The level of glycemia in patients with severe versus 
very severe COPD 
Variable Group Mean ± SD Min - Max p-value 
Glycemia 
(mmol/l) 
Severe 5.62 ± 0.9 4.6 – 8.6 
*p =0.018 
Very severe 7.67 ± 3.7 4.5 – 15.3 
     
*p ( Student-s t-test). 
 
Men with severe and very severe COPD had 
insignificant higher average value of blood glucose 
than women (5.68 ± 0.9 vs. 5.54 ± 1.0 and 8.0 ± 3.6 
vs. 6.03 ± 1.3 consequently) (Table 6). 
Table 5: The level of HbA1c in patients with severe versus very 
severe COPD 
Variable Group Mean ± SD Median (IQR) p-value 
HbA1c % Severe 5.6 ± 0.9 5.5 (.5 - 6.25)  
   *p < 0.0001 Very severe 6.25 ± 1.8 5.25 (5 –8.25) 
P (Mann- Whitney U test). 
 
In the group with severe COPD, HbA1c 
positively correlated with BMI (r = 0.318, p = 0.01), 
cholesterol (r = 0.239, p = 0.057) and LDL (r = 0.314 = 
0.012), and significantly negatively correlates with 
HDL (r = - 0.433, p <0.001). 
Table 6: The average value of blood glucose in female vs. male 
in both groups   
COPD 
Group 
Gender 
   Descriptive statistic glycaemia 
         p-value 
      Max ± SD                 Min - Max 
Severe 
Female n=28     5.54 ±1.0                4.6 – 7.9 
        *p = 0.5 
Male n=36     5.68 ± 0.9                4.7 – 8.6 
Very severe 
Female n=6     6.03 ± 1.3                4.7 – 7.7 
        *p = 0.2 
Male n=30     8.0 ± 3.6                4.5 –  15.3 
*p (Student-s t-test); **p (Mann-Whitney U test). 
 
In the group with very severe COPD, 
cholesterol significantly positively correlated with LDL 
(r = 0.896, p <0.001) and HbA1c (r = 0.79, p <0.001), 
while significantly negatively correlated with the age of 
patients (r = - 0.458, p = 0.005) and the values of 
FVC% (r = - 0.37, p = 0.025) and HDL (r = - 0.793, p 
<0.001) (Table 7). 
Table 7: The correlation of HbA1c with age, functional 
parameters, BMI, cholesterol, LDL, HDL 
Correlation cholesterol / r  - Pearson 
Severe Very severe 
Age (years) r = 0.07,  p=0.57 r = - 0.428,  p=0.006 
FVC L r =  0.173,  p=0.17 r = - 0.033,  p=0.8 
FVC% r =  0.159,  p=0.21 r = - 0.146,  p=0.4 
FEV1 L r = - 0.05,  p=0.69 r = - 0.065,  p=0.7 
FEV1 % r =  - 0.05,  p=0.9 r = - 0.238,  p=0.16 
FEV1/FVC% r =  - 0.075,  p=0.55 r =  0.07,  p=0.68 
BMI r =  0.318,  p=0.01 r =  0.144,  p=0.4 
Cholesterol (mmol/l) r =  0.239,  p=0.057 r =  0.792,  p<0.001 
LDL (mmol/l) r =  0.314,  p=0.012 r =  0.688 , p<0.001 
HDL (mmol/l) r =  - 0.433,  p<0.001 r =  - 0.793,  p<0.001 
 
Results from Multiple regression analysis 
which investigate the impact of BMI, LDL and HDL 
glucose, in the group with severe COPD, (which 
bivarijant analysis proved to be significantly related to 
blood glucose) not confirmed any factor with 
significant predictive effect on the values of glycemia. 
HbA1c = 4,1768 + ,05952 * BMI
Correlation: r = ,31810
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Figure 1: Correlation – HbA1c vs. BMI and LDL in the group with 
severe COPD  
 
As independent significant factors that affect 
blood glucose in a group of very severe COPD 
confirmed cholesterol (p <0.0001) and HDL (p = 
0.018). 
With increasing values of cholesterol to 
1mmol/l , the values of average glycemia increased to 
2.798 (B = 2.798), while an increase in HDL values at 
1 mmol/l, the values of average blood glucose 
increase to 3.489 (B = 3.489). 
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HbA1c = 18,424 - ,1739  * age
Correlation: r = -,4281
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Figure 2: Correlation - HbA1c vs.  LDL and age in the group with 
very severe COPD  
 
These results suggest that the presence of 
the COPD in patients itself is a factor that results in 
the clinical presentation of diabetes mellitus Type 2. 
The patients with very severe COPD more likely have 
diabetes mellitus Type 2. Results from Multiple 
regression analysis which investigate the impact of 
BMI, LDL and HDL glucose, in the group with severe 
COPD, (which bivariate analysis proved to be 
significantly related to blood glucose) not confirmed 
any factor with significant predictive effect on the 
values of glycaemia. As independent significant 
factors that affect blood glucose in a group of very 
severe COPD confirmed cholesterol (p <0.0001) and 
HDL (p = 0.018). 
HbA1c  = 6,5305 - ,6963  * HDL
Correlation: r = -,4332
0,2 0,4 0,6 0,8 1,0 1,2 1,4 1,6 1,8 2,0 2,2 2,4
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HbA1c = -3,815 + 1,8645 * holesterol
Correlation: r = ,79202
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Figure 3: Correlation - HbA1c vs.  HDL and cholesterol in the group 
with a very severe COPD  
 
 
Discussion 
 
Disturbances in glucose metabolism are more 
common in COPD patients than in subjects without 
COPD. COPD, metabolic syndrome and diabetes 
mellitus type 2 are associated with advanced age. It is 
well known that offspring of affected parents are more 
likely to develop both COPD and type 2 diabetes 
mellitus. Smoking during pregnancy can in part 
explain the association between COPD and type 2 
diabetes mellitus [11, 12]. 
According to data from the International 
Federation and diabetes data of the National Registry 
of diabetes, incidence of the disease in Macedonia in 
2012 was 6.9 % , and the total number of diagnosed 
persons with diabetes was 119 200 [14]. 
Table 8: Multiple regression analysis of the impact of BMI, LDL 
and HDL on the glucose in the group with severe COPD 
Coefficients 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients t 
 
 Sig. 
95% Confidence 
Interval for B 
B 
Std. 
Error 
Beta Lower 
Bound 
Upper 
Bound 
1           
(Constant) 
5.636 1.304  4.323 0.000 3.028 8.243 
          BMI 0.029 0.026 0.155 1.137 0.260 -0.022 0.080 
          LDL -0.570 0.344 -0.355 -1.655 0.103 -1.259 0.119 
          HDL  0.009 0.164 0.010 0.053 0.958 -0.318 0.336 
a. a) Dependent Variable: glycemia.   
 
 
In our survey the prevalence of Diabetes 
mellitus type 2 in COPD patients was 21%. 
According study from 2015, Paola Rogliani, 
the prevalence between diabetes and COPD varies 
between studies reported; however it is known that 
diabetes affects 2–37 % of patients with COPD [14]. 
Table 9: Multiple regression analysis of the impact of age, LDL, 
HDL cholesterol and glucose in a very severe group COPD 
Coefficients 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95% Confidence 
Interval for B 
B 
Std. 
Error 
Beta Lower 
Bound 
Upper 
Bound 
1           
(Constant) 
-18.160 7.696  -2.360 0.025 -33.856 -2.464 
             Age 0.062 0.060 0.154 1.049 0.302 -0.059 0.184 
             
Cholesterol 
2.798 0.623 1.189 4.489 0.000 1.527 4.069 
             LDL 0.276 0.511 0.131 0.540 0.593 -0.767 1.318 
             HDL 3.489 1.399 0.560 2.493 0.018 0.635 6.343 
a
) Dependent Variable: glycemia. 
 
The reported prevalence of diabetes among 
patients with COPD ranges from 1.6 to 16%. As in 
COPD, smoking has been established as a risk factor 
for diabetes, quitting for more than 5 to 10 years 
mitigates that risk. Type 2 diabetes is more prevalent 
in moderate-to-very severe (but not mild) COPD than 
in the general population, with an overall prevalence 
of 12.7% in the combined ARIC and CHS cohorts and 
12.2% in The Health Improvement Network dataset. 
The evidence for an interaction between diabetes and 
COPD is supported by studies that demonstrate 
reduced lung function as a risk factor for the 
development of diabetes. Inflammatory mediators 
such as TNF-α, IL-6, and CRP, which are elevated in 
COPD, are also increased in diabetes [10]. The 
impact of parental use of corticosteroids on the 
management of diabetes during COPD exacerbations 
and the effect of diabetes control on COPD outcomes 
is of great clinical concern. Mortality was found to be 
significantly higher in patients having poor glycemic 
control who were hospitalized for acute COPD 
exacerbation, and even after discharge, diabetes 
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remained a risk factor for mortality. It is uncertain if 
tighter and better glucose control can improve COPD 
outcome [7]. 
The level of C-reactive protein in our patients 
with very severe stage of COPD was significantly 
higher versus patients with severe COPD (p < 
0.0001). 
According Gregory L Kinney, people with 
diabetes mellitus have a 22% increased risk of 
developing chronic obstructive pulmonary disease, 
whereas those with chronic obstructive pulmonary 
disease have a 40–100% increased risk of developing 
diabetes [16]. 
In the United States they have estimated a 
prevalence of diabetes of 12.7% to 16.3% among 
patients with COPD, significantly higher than in the 
general population. Longitudinal studies have 
confirmed that COPD is a risk factor for incident 
diabetes [17]. 
A recent review of the literature established 
the complex link between smoking and obesity in the 
development of co-morbidities, involving an enzyme 
cascade that originates in adipose tissue considered a 
site for production of cytokines (TNF-a, IL-6, etc), 
while adiponectin decreases with increased adiposity. 
This increases insulin resistance, circulating free 
radicals and oxidative stress, exacerbating the initial 
pulmonary inflammation. Adipose tissue stimulation is 
promoted by tissue hypoxia, smoking and the degree 
of bronchial obstruction. Severity of systemic 
inflammation is a direct measure of severity of COPD. 
In Vinay Mahishale study, more than two-third of the 
subjects had moderate to severe COPD who had DM, 
which is in agreement with many cohort studies which 
have demonstrated that moderate to severe COPD 
increases the risk of DM (OR 1.4 and 1.5, 
respectively) [18-21]. 
Conversely, in a US cohort, the relative risk of 
developing COPD was higher (HR 1.22) in patients 
with diabetes than in non-diabetics. It is well known 
fact that DM significantly affects the outcome of 
COPD including time to first hospitalization and 5-
years mortality rates. According to the Emerging Risk 
Factors Collaboration, the HR for COPD-related death 
was 1.27 as compared to subjects without diabetes. 
Another study showed that an increase in blood 
glucose of 1 mmol/L increases the risk of death by 
15%. Parrapil et al. and Baker et al., confirmed an 
increased risk of death (OR 1.93) and hospital stays 
were 10.3% longer for patients with diabetes 
hospitalized for COPD exacerbation [22-25]. 
Prevalence of DM in COPD patients in 
Mannino DM, study is 25.63% when actively screened 
in tertiary care hospital. It is feasible and imperative to 
screen all COPD patients for DM in all health care 
facilities routinely [23, 26]. 
In study of Zareen Kiran, forty COPD patients 
were compared with thirty five age match controls. 
HOMA-IR (insulin resistance) was found to be higher 
in cases as compared to controls (2.85 v/s 2.00) with 
a p value <0.000 [27] 
In conclusion, the definition of COPD as 
primarily a lung disease has been changed, and now 
the broader definition of COPD as a systemic 
inflammatory syndrome has been proposed. There is 
increasing evidence that another disease occur in 
greater frequency amongst patients with COPD than 
in the general population, and that these comorbidities 
significantly impact on patient outcomes. Evidence for 
this approach has been provided by strong 
associations with increased rates especially with 
cardiovascular diseases, metabolic syndrome, 
anemia, musculoskeletal disease and malignances. 
From the results of our survey COPD itself is a factor 
that leads to clinical presentation of diabetes mellitus 
Type 2.  
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